Addressing the dichotomy between individual and societal approaches to personalised medicine in oncology

the IBCD-Faculty

Research output: Contribution to journalArticle

Abstract

Academic, industry, regulatory leaders and patient advocates in cancer clinical research met in November 2018 at the Innovation and Biomarkers in Cancer Drug Development meeting in Brussels to address the existing dichotomy between increasing calls for personalised oncology approaches based on individual molecular profiles and the need to make resource and regulatory decisions at the societal level in differing health-care delivery systems around the globe. Novel clinical trial designs, the utility and limitations of real-world evidence (RWE)and emerging technologies for profiling patient tumours and tumour-derived DNA in plasma were discussed. While randomised clinical trials remain the gold standard approach to defining clinical utility of local and systemic therapeutic interventions, the broader adoption of comprehensive tumour profiling and novel trial designs coupled with RWE may allow patient and physician autonomy to be appropriately balanced with broader assessments of safety and overall societal benefit.

Original languageEnglish (US)
Pages (from-to)128-136
Number of pages9
JournalEuropean Journal of Cancer
Volume114
DOIs
StatePublished - Jun 1 2019

Fingerprint

Precision Medicine
Neoplasms
Delivery of Health Care
Tumor Biomarkers
Industry
Randomized Controlled Trials
Clinical Trials
Technology
Physicians
Safety
DNA
Research
Pharmaceutical Preparations
Therapeutics

Keywords

  • Biomarkers
  • Clinical trials
  • Evidence-driven optimal health-care delivery
  • Health technology assessment
  • Molecular and immunologic profiling

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Addressing the dichotomy between individual and societal approaches to personalised medicine in oncology. / the IBCD-Faculty.

In: European Journal of Cancer, Vol. 114, 01.06.2019, p. 128-136.

Research output: Contribution to journalArticle

@article{38986c34a3734fb09f16823ec9dc1db2,
title = "Addressing the dichotomy between individual and societal approaches to personalised medicine in oncology",
abstract = "Academic, industry, regulatory leaders and patient advocates in cancer clinical research met in November 2018 at the Innovation and Biomarkers in Cancer Drug Development meeting in Brussels to address the existing dichotomy between increasing calls for personalised oncology approaches based on individual molecular profiles and the need to make resource and regulatory decisions at the societal level in differing health-care delivery systems around the globe. Novel clinical trial designs, the utility and limitations of real-world evidence (RWE)and emerging technologies for profiling patient tumours and tumour-derived DNA in plasma were discussed. While randomised clinical trials remain the gold standard approach to defining clinical utility of local and systemic therapeutic interventions, the broader adoption of comprehensive tumour profiling and novel trial designs coupled with RWE may allow patient and physician autonomy to be appropriately balanced with broader assessments of safety and overall societal benefit.",
keywords = "Biomarkers, Clinical trials, Evidence-driven optimal health-care delivery, Health technology assessment, Molecular and immunologic profiling",
author = "{the IBCD-Faculty} and Roberto Salgado and Solit, {David B.} and Rimm, {David L.} and Jan Bogaerts and Renzo Canetta and Tracy Lively and Kim Lyerly and Span, {Paul N.} and Alison Bateman-House and Amr Makady and L. Bergmann and Sumimasa Nagai and Chris Smith and Mark Robson and Mary Savage and Emile Voest and Christopher Sweeney and Philippe Lambin and Marlene Thomas and Lyndsay Harris and Denis Lacombe and Chistophe Massard and Rene Bernards and Richard Sullivan and Sabine Tejpar and Nina Lukinova and Lyerly, {Herbert K.} and Helen Moore and Smith, {Malcolm A.} and Laura Yee and Ray DuBois and Hahn, {William C.} and Pasi Janne and Willman, {Cheryl L.} and David Rimm and Lothar Bergmann and Cree, {Ian A.} and Priti Hegde and Shirley Hopper and Marc Robson and Magnus Ingelman-Sundberg and Gwen Nichols and Francois Maignen and Benjamin Besse and Rafal Swierzewski and Astrid Kiermaier and Christophe Massard and Michael Caliguri and Velculescu, {Victor E} and Paolo Foggi",
year = "2019",
month = "6",
day = "1",
doi = "10.1016/j.ejca.2019.03.025",
language = "English (US)",
volume = "114",
pages = "128--136",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Addressing the dichotomy between individual and societal approaches to personalised medicine in oncology

AU - the IBCD-Faculty

AU - Salgado, Roberto

AU - Solit, David B.

AU - Rimm, David L.

AU - Bogaerts, Jan

AU - Canetta, Renzo

AU - Lively, Tracy

AU - Lyerly, Kim

AU - Span, Paul N.

AU - Bateman-House, Alison

AU - Makady, Amr

AU - Bergmann, L.

AU - Nagai, Sumimasa

AU - Smith, Chris

AU - Robson, Mark

AU - Savage, Mary

AU - Voest, Emile

AU - Sweeney, Christopher

AU - Lambin, Philippe

AU - Thomas, Marlene

AU - Harris, Lyndsay

AU - Lacombe, Denis

AU - Massard, Chistophe

AU - Bernards, Rene

AU - Sullivan, Richard

AU - Tejpar, Sabine

AU - Lukinova, Nina

AU - Lyerly, Herbert K.

AU - Moore, Helen

AU - Smith, Malcolm A.

AU - Yee, Laura

AU - DuBois, Ray

AU - Hahn, William C.

AU - Janne, Pasi

AU - Willman, Cheryl L.

AU - Rimm, David

AU - Bergmann, Lothar

AU - Cree, Ian A.

AU - Hegde, Priti

AU - Hopper, Shirley

AU - Robson, Marc

AU - Ingelman-Sundberg, Magnus

AU - Nichols, Gwen

AU - Maignen, Francois

AU - Besse, Benjamin

AU - Swierzewski, Rafal

AU - Kiermaier, Astrid

AU - Massard, Christophe

AU - Caliguri, Michael

AU - Velculescu, Victor E

AU - Foggi, Paolo

PY - 2019/6/1

Y1 - 2019/6/1

N2 - Academic, industry, regulatory leaders and patient advocates in cancer clinical research met in November 2018 at the Innovation and Biomarkers in Cancer Drug Development meeting in Brussels to address the existing dichotomy between increasing calls for personalised oncology approaches based on individual molecular profiles and the need to make resource and regulatory decisions at the societal level in differing health-care delivery systems around the globe. Novel clinical trial designs, the utility and limitations of real-world evidence (RWE)and emerging technologies for profiling patient tumours and tumour-derived DNA in plasma were discussed. While randomised clinical trials remain the gold standard approach to defining clinical utility of local and systemic therapeutic interventions, the broader adoption of comprehensive tumour profiling and novel trial designs coupled with RWE may allow patient and physician autonomy to be appropriately balanced with broader assessments of safety and overall societal benefit.

AB - Academic, industry, regulatory leaders and patient advocates in cancer clinical research met in November 2018 at the Innovation and Biomarkers in Cancer Drug Development meeting in Brussels to address the existing dichotomy between increasing calls for personalised oncology approaches based on individual molecular profiles and the need to make resource and regulatory decisions at the societal level in differing health-care delivery systems around the globe. Novel clinical trial designs, the utility and limitations of real-world evidence (RWE)and emerging technologies for profiling patient tumours and tumour-derived DNA in plasma were discussed. While randomised clinical trials remain the gold standard approach to defining clinical utility of local and systemic therapeutic interventions, the broader adoption of comprehensive tumour profiling and novel trial designs coupled with RWE may allow patient and physician autonomy to be appropriately balanced with broader assessments of safety and overall societal benefit.

KW - Biomarkers

KW - Clinical trials

KW - Evidence-driven optimal health-care delivery

KW - Health technology assessment

KW - Molecular and immunologic profiling

UR - http://www.scopus.com/inward/record.url?scp=85065035041&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065035041&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2019.03.025

DO - 10.1016/j.ejca.2019.03.025

M3 - Article

C2 - 31060925

AN - SCOPUS:85065035041

VL - 114

SP - 128

EP - 136

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

ER -